Japan's biggest drug maker is making eyes at the US market as its patents get closer to their expiration dates. Takeda Pharmaceutical said it would pay $100 million to be Alnylam Pharmaceuticals' strategic partner in RNAi therapeutics, says the Wall Street Journal.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.